Department of Allergy and Clinical Immunology, Graduate School of Medicine, Japan.
Department of Infectious Diseases, Chiba University Hospital, Japan.
Clin Microbiol Infect. 2021 Dec;27(12):1861.e1-1861.e5. doi: 10.1016/j.cmi.2021.07.042. Epub 2021 Aug 8.
This study aimed to determine antibody responses in healthcare workers who receive the BNT162b2 mRNA COVID-19 vaccine and identify factors that predict the response.
We recruited healthcare workers receiving the BNT162b2 mRNA COVID-19 vaccine at the Chiba University Hospital COVID-19 Vaccine Center. Blood samples were obtained before the 1st dose and after the 2nd dose vaccination, and serum antibody titers were determined using Elecsys® Anti-SARS-CoV-2S, an electrochemiluminescence immunoassay. We established a model to identify the baseline factors predicting post-vaccine antibody titers using univariate and multivariate linear regression analyses.
Two thousand fifteen individuals (median age 37-year-old, 64.3% female) were enrolled in this study, of which 10 had a history of COVID-19. Before vaccination, 21 participants (1.1%) had a detectable antibody titer (≥0.4 U/mL) with a median titer of 35.9 U/mL (interquartile range [IQR] 7.8 - 65.7). After vaccination, serum anti-SARS-CoV-2S antibodies (≥0.4 U/mL) were detected in all 1774 participants who received the 2nd dose with a median titer of 2060.0 U/mL (IQR 1250.0 - 2650.0). Immunosuppressive medication (p < 0.001), age (p < 0.001), time from 2nd dose to sample collection (p < 0.001), glucocorticoids (p = 0.020), and drinking alcohol (p = 0.037) were identified as factors predicting lower antibody titers after vaccination, whereas previous COVID-19 (p < 0.001), female (p < 0.001), time between 2 doses (p < 0.001), and medication for allergy (p = 0.024) were identified as factors predicting higher serum antibody titers.
Our data demonstrate that healthcare workers universally have good antibody responses to the BNT162b2 mRNA COVID-19 vaccine. The predictive factors identified in our study may help optimize the vaccination strategy.
本研究旨在确定接种 BNT162b2 mRNA COVID-19 疫苗的医护人员的抗体反应,并确定预测反应的因素。
我们在千叶大学医院 COVID-19 疫苗中心招募了接种 BNT162b2 mRNA COVID-19 疫苗的医护人员。在第 1 剂和第 2 剂接种后采集血样,并使用电化学发光免疫分析法 Elecsys® Anti-SARS-CoV-2S 测定血清抗体滴度。我们使用单变量和多变量线性回归分析建立了一个模型,以确定预测疫苗接种后抗体滴度的基线因素。
本研究共纳入 2015 名参与者(中位年龄 37 岁,64.3%为女性),其中 10 名有 COVID-19 病史。接种前,21 名参与者(1.1%)的抗体滴度(≥0.4 U/mL)可检测到,中位数为 35.9 U/mL(四分位距 [IQR] 7.8-65.7)。接种第 2 剂后,1774 名接受第 2 剂接种的参与者均检测到血清抗 SARS-CoV-2S 抗体(≥0.4 U/mL),中位数为 2060.0 U/mL(IQR 1250.0-2650.0)。免疫抑制药物(p<0.001)、年龄(p<0.001)、从第 2 剂到样本采集的时间(p<0.001)、糖皮质激素(p=0.020)和饮酒(p=0.037)被确定为接种后抗体滴度较低的预测因素,而既往 COVID-19(p<0.001)、女性(p<0.001)、两剂之间的时间(p<0.001)和过敏药物(p=0.024)被确定为血清抗体滴度较高的预测因素。
我们的数据表明,医护人员普遍对 BNT162b2 mRNA COVID-19 疫苗有良好的抗体反应。我们研究中确定的预测因素可能有助于优化疫苗接种策略。